Jaguar Health Provides Update Regarding Special Stock Dividend
Stockholders selling common shares during the dividend right period also sell their right to the special stock dividend.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Jaguar Health (JAGX) announced that Nasdaq indicated October 16, 2026, as the ex-dividend date for its special stock dividend.
The dividend consists of Series R Convertible Preferred Stock and is payable October 15, 2026, to common stockholders and holders of certain outstanding warrants of record on October 13, 2026. Common shares will trade with due bills, which transfer dividend rights to buyers, from the record date until the ex-dividend date.
Jaguar also plans to file a New Drug Application in mid-2027 for crofelemer to treat microvillus inclusion disease, a rare intestinal failure disease.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Special stock dividend distributes Series R Convertible Preferred Stock, payable October 15, 2026, to eligible holders.
- Minor point. Forward-looking: it has not happened yet and may not happen.Crofelemer application for microvillus inclusion disease is planned for mid-2027.
Negative
- None.
News Explained
For trades during the dividend-right period, sellers must deliver the dividend to buyers; the brokers customarily settle that obligation, and Jaguar says it is not responsible for the due-bill amount or processing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, CA / ACCESS Newswire / October 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today provided an update in connection with the Company's previously announced special stock dividend (the "Special Stock Dividend"), which is payable on October 15, 2026, to holders of Jaguar common stock and certain outstanding warrants as of record on October 13, 2026, to announce that The Nasdaq Stock Market LLC ("Nasdaq") has indicated that the ex-dividend date for the Special Stock Dividend is October 16, 2026 (the "Ex-Dividend Date"). The Special Stock Dividend consists of the Company's Series R Convertible Preferred Stock (the "Preferred Stock").
Nasdaq has advised the Company that its shares of common stock will trade with "due bills" representing an assignment of the right to receive the dividend from the record date of October 13, 2026 until the Ex-Dividend Date (this period of time representing the "Dividend Right Period").
Stockholders who sell their shares of common stock during the Dividend Right Period will be selling their right to the Special Stock Dividend. Due bills obligate a seller of shares of common stock to deliver the Special Stock Dividend payable on such shares of common stock to the buyer (the "Dividend Right"). The record date of October 13, 2026, will be used as the date for establishing the due bill tracking of the Dividend Right to the holder of shares of common stock.
Due bill obligations are customarily settled between the brokers representing the buyers and the sellers of shares of common stock. The Company has no obligation for either the amount of the due bill or the processing of the due bill. Buyers and sellers of the Company's shares of common stock should consult their brokers before trading to be sure they understand the effect of Nasdaq's due bill procedures.
"Jaguar is issuing the Special Stock Dividend to reward and recognize our passionate and supportive stockholders and provide protection against potential dilution as we continue evaluation of strategic alternatives," said Lisa Conte, Jaguar's founder, president, and CEO. "We remain sharply focused on our ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support for rare intestinal failure diseases, including microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) for crofelemer powder for oral solution. Jaguar's intestinal failure program is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027."
For additional information about the Special Stock Dividend and terms of the Preferred Stock and associated risk factors, please refer to the Form 8-K the Company filed with the U.S. Securities and Exchange Commission on October 5, 2026, which can be viewed on the Company's website by clicking here.
About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals, Inc. (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding payment of dividends, conversion of the Preferred Stock, Jaguar's expectation that its intestinal failure program will continue to provide clinical proof-of-concept milestones, and Jaguar's expectation that the Company will file an NDA with the U.S. Food and Drug Administration for the MVID indication in mid-2027. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is Jaguar Health's special stock dividend payable, and what is the ex-dividend date?
The special stock dividend is payable October 15, 2026, and Nasdaq indicated an ex-dividend date of October 16, 2026. It consists of Series R Convertible Preferred Stock, with an October 13, 2026, record date for common stockholders and holders of certain outstanding warrants.